Aumolertinib is a 3rd generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI), that has demonstrated significant benefits compared to standard first-line treatments of 1st and 2nd generations in the WHO Essential Medicines List for the treatment of non-small cell lung cancer. Aumolertinib is under review for approval by the European Medicines Agency (EMA).